Alerts
Holiday Hours Information

In recognition of the Christmas and New Year’s holidays, some of The University of Kansas Cancer Center’s offices will have modified hours on Wednesday, December 25, and Wednesday, January 1.

More info
Skip Navigation
Back to search results

A Phase III, Multicenter, Randomized, Open-label, Parallel group, Treatment Study to Assess the Efficacy and Safety of the Lifileucel LN-144, Autologous Tumor-infiltrating Lymphocytes [TIL] Regimen in Combination with Pembrolizumab Compared with Pembrolizumab Monotherapy in Participants with Untreated, Unresectable or Metastatic Melanoma

Brief Summary

Type:
Melanoma

Study Type:
Treatment

Phase:
III

ClinicalTrials.gov Identifier:
NCT05727904

Study #:
STUDY00150623

Start Date:
Feb 12, 2024

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT05727904

View Complete Trial Details & Eligibility at ClinicalTrials.gov

To request an appointment, call 844-323-1227.